CA2248932A1 - Oligonucleotides cibles sur l'arnm de l'angiotensinogene - Google Patents

Oligonucleotides cibles sur l'arnm de l'angiotensinogene Download PDF

Info

Publication number
CA2248932A1
CA2248932A1 CA002248932A CA2248932A CA2248932A1 CA 2248932 A1 CA2248932 A1 CA 2248932A1 CA 002248932 A CA002248932 A CA 002248932A CA 2248932 A CA2248932 A CA 2248932A CA 2248932 A1 CA2248932 A1 CA 2248932A1
Authority
CA
Canada
Prior art keywords
mrna
angiotensinogen
human
antisense
oligonucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002248932A
Other languages
English (en)
Inventor
Donna Wielbo
M. Ian Phillips
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
University of Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Florida filed Critical University of Florida
Publication of CA2248932A1 publication Critical patent/CA2248932A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/311—Phosphotriesters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3511—Conjugate intercalating or cleaving agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3535—Nitrogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des oligonucléotides et des compositions de ces derniers qui peuvent être administrés à l'homme pour inhiber l'expression de l'angiotensinogène. Cela permet ainsi de combattre l'hypertension induite par l'angiotensinogène.
CA002248932A 1996-03-15 1997-03-14 Oligonucleotides cibles sur l'arnm de l'angiotensinogene Abandoned CA2248932A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61686096A 1996-03-15 1996-03-15
US08/616,860 1996-03-15

Publications (1)

Publication Number Publication Date
CA2248932A1 true CA2248932A1 (fr) 1997-09-18

Family

ID=24471266

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002248932A Abandoned CA2248932A1 (fr) 1996-03-15 1997-03-14 Oligonucleotides cibles sur l'arnm de l'angiotensinogene

Country Status (5)

Country Link
EP (1) EP0906123A4 (fr)
JP (1) JP2000506866A (fr)
AU (1) AU2529697A (fr)
CA (1) CA2248932A1 (fr)
WO (1) WO1997033623A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9509798A (en) 1997-09-25 1999-04-12 University Of Florida Antisense oligonucleotide compositions targeted to angiotensi n converting enzy me mrna and methods of use
WO2014018930A1 (fr) 2012-07-27 2014-01-30 Isis Pharmaceuticals. Inc. Modulation de maladies associées au système rénine—angiotensine (ras) par l'angiotensinogène
SG11201507496UA (en) 2013-04-17 2015-11-27 Pfizer N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
CA2998898A1 (fr) * 2015-10-08 2017-04-13 Ionis Pharmaceuticals, Inc. Composes et procedes pour moduler l'expression de l'angiotensinogene
CA3201661A1 (fr) 2020-11-18 2022-05-27 Ionis Pharmaceuticals, Inc. Composes et procedes pour moduler l'expression de l'angiotensinogene
CN113862268A (zh) * 2021-10-20 2021-12-31 厦门甘宝利生物医药有限公司 Agt抑制剂及其用途
WO2023088227A1 (fr) * 2021-11-16 2023-05-25 上海舶望制药有限公司 Composition et procédé d'inhibition de l'expression de la protéine angiotensinogène (agt)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631237A (en) * 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes

Also Published As

Publication number Publication date
WO1997033623A1 (fr) 1997-09-18
EP0906123A1 (fr) 1999-04-07
EP0906123A4 (fr) 1999-05-26
AU2529697A (en) 1997-10-01
JP2000506866A (ja) 2000-06-06

Similar Documents

Publication Publication Date Title
US6849726B2 (en) Non-nucleotide containing RNA
US5747470A (en) Method for inhibiting cellular proliferation using antisense oligonucleotides to gp130 mRNA
US6846921B2 (en) Chimeric antisense oligonucleotides and cell transfecting formulations thereof
US6312900B1 (en) Antisense oligonucleotide compositions and methods for the modulation of activating protein 1
EP0677056B1 (fr) Alkylphosphonates et alkylphosphonothioates d'oligonucleotides
US5989906A (en) Method and reagent for inhibiting P-glycoprotein (mdr-1-gene)
JP3121599B2 (ja) ｒａｆ遺伝子発現のアンチセンスオリゴヌクレオチド調節
EP0736093B1 (fr) ACIDES NUCLEIQUES ANTI-SENS DESTINES A LA PREVENTION ET AU TRAITEMENT DE TROUBLES DANS LESQUELS INTERVIENT L'EXPRESSION DE c-erbB-2
Jaroszewski et al. Cellular uptake of antisense oligodeoxynucleotides
US5739309A (en) Enhancement of oligonucleotide inhibition of protein production, cell proliferation and / or multiplication of infectious disease pathogens
JPH09504297A (ja) ２′−アミドおよび２′−ペプチド修飾オリゴヌクレオチド
CA2163234A1 (fr) Inhibition de la proliferation des cellules vasculaires du muscle lisse
JPH08502950A (ja) 癌増殖を抑制する方法及び試薬
US20050153312A1 (en) Nucleic acid compositions and methods of introducing nucleic acids into cells
EP0781332A2 (fr) Augmentation de l'inhibition oligonucleotidique de la production proteique, de la proliferation cellulaire et/ou de la multiplication d'agents pathogenes de maladie infectieuse
WO1995003406A9 (fr) Augmentation de l'inhibition oligonucleotidique de la production proteique, de la proliferation cellulaire et/ou de la multiplication d'agents pathogenes de maladie infectieuse
JP2003505517A (ja) 接合体ならびにそれらの製造方法および生体膜を横切り分子を輸送するためのそれらの使用
CA2248932A1 (fr) Oligonucleotides cibles sur l'arnm de l'angiotensinogene
US20020102694A1 (en) Nucleozymes with endonuclease activity
Tomita et al. Effect of angiotensinogen on blood pressure regulation in normotensive rats: application of a loss of function approach
Wielbo et al. Antisense inhibition of angiotensinogen in hepatoma cell culture is enhanced by cationic liposome delivery
US5780612A (en) Oligonucleotides specific for cytokine signal transducer gp130 mRNA
EP0906421A1 (fr) Efficacite amelioree d'apport liposomal de molecules anti-sens
EP0747480A1 (fr) Oligonucléotides spécifiques de l'ARNm du transducteur de signal pour les cytokines gp130

Legal Events

Date Code Title Description
FZDE Dead